19 June 2026
19 June 2026
GlobalData says that the industry has “absorbed significant disruption”, with high M&A levels testament to recovery.
Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing industry.
uniQure confirmed it will submit its BLA in Q3 2026, though there is still a required confirmatory study to conduct.
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
The new arrangement between Voro and Alloy centres on finding approaches that may enhance the therapeutic index of TCE therapies.
AbCellera will conduct discovery and early-stage research activities on two initial programmes.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
